PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.
Jun Ma(Sun Yat-sen University), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse), G. Hu(Dalian University), Xu Liu(Hengyang Normal University), Shubin Hong(Sun Yat-sen University), Guorong Zou(Panyu District Central Hospital), Yawei Yuan(Ruijin Hospital), Ying Sun(Key Laboratory of Guangdong Province), Feng Jin(China Medical University), Kunyu Yang(Macau University of Science and Technology), Ning Zhang(First People's Hospital of Foshan), Liangfang Shen(Central South University), Chuanben Chen(Fujian Medical University), Hongyun Zhao(Sun Yat-sen University), Xiao-Dong Zhu, Ye‐Lin Liang(Sun Yat-sen University), Xiaozhong Chen(Zhejiang Cancer Hospital)
Cited by 2
Related Papers
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
|Cell Research|2020|483
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
|Journal of Clinical Oncology|2021|393
Microneedle-mediated transdermal drug delivery for treating diverse skin diseases
|Acta Biomaterialia|2020|247